Researchers report TNFR1 signaling connects systemic inflammation to impaired fatty acid oxidation in intestinal stem cell aging

A study in Nature Aging demonstrates that systemic TNF-mediated TNFR1 signaling drives intestinal stem cell aging by impairing mitochondrial fatty acid oxidation, a decline that can be reversed by systemic anti-inflammatory interventions.

Researchers reported that heterochronic parabiosis physically pairing young and old mice propagates the intestinal stem cell (ISC) aging phenotype from old to young animals.

The study found that knockout of tumor necrosis factor receptor 1 (TNFR1) specifically in the intestinal epithelium protected young ISCs from the progeronic effects of the old systemic environment.

In young organoids, exposure to the progeronic factor TNF triggered a downregulation of fatty acid oxidation (FAO) genes, including Cpt1a, Fabp1, Fabp2, Pparg, and Ppara, and attenuated maximal respiration.

Systemic administration of anti-inflammatory agents—including rapamycin, salicylate, aspirin, and neutralizing antibodies against TNF or IFNγ—restored organoid-forming capacity in aged mice.

Conversely, treatment with 5-aminosalicylic acid (5-ASA), which is confined mainly to the intestinal lumen, failed to rescue the aged ISC phenotype, suggesting that systemic rather than gut-specific inflammation drives the decline.

It establishes a direct, cell-nonautonomous link between whole-body inflammaging and localized somatic stem cell exhaustion via TNFR1 signaling.

The study identifies mitochondrial FAO as a primary metabolic node that is functionally suppressed by chronic inflammatory signaling, but remains malleable and pharmacologically rescueable.

It demonstrates that the age-associated decline in stem cell resilience to injury (such as radiation) is tied to a failure to induce survival factors like clusterin, which is also influenced by systemic inflammatory tone.

This research validates longevity pipelines exploring systemic immunomodulation and mitochondrial dynamics to address age-related tissue degeneration.

It suggests that therapeutics targeting systemic cytokines (TNF or IFNγ) or metabolic pathways (like PPAR-regulated lipid metabolism and mitochondrial fusion) could be repurposed or developed to target stem cell exhaustion in older adults.

Further preclinical and clinical exploration of systemically acting salicylates or targeted anti-TNF therapies to improve gut barrier integrity and stem cell homeostasis in aging populations.

Investigating if similar systemic TNFR1-mediated metabolic suppression occurs in other solid-organ somatic stem cell niches.